Results 221 to 230 of about 211,411 (286)

Diabetic retinopathy in Greenland and Denmark—Can differences in risk factors explain the lower prevalence in Greenland?

Acta Ophthalmologica, EarlyView.
Abstract Purpose The prevalence of diabetic retinopathy (DR) is low in Greenland. Factors underlying the low prevalence may potentially protect against the development of DR. Comparing Greenlandic and Danish populations, this register‐based study explored differences in risk factors that may explain differences in DR prevalence.
Jonas Bjørn Skjøth, Helene Nielsen, Marie Ørskov, Lasse Cehofski, Stine Byberg   +4 more
wiley   +1 more source

MCV/Q, Medical College of Virginia Quarterly, Vol. 14 No. 3 [PDF]

, 1978

core   +1 more source

Case Report: Glomerular microangiopathy and reversible renal toxicity during prolonged bevacizumab therapy in ovarian cancer. [PDF]

Front Oncol
Kwon J, Choe M, Paek JH, Park WY, Jin K, Han S, Cho CH, Kim Y.   +7 more
europepmc   +1 more source

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

British Journal of Haematology, EarlyView.
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, Gianmarco Favrin, Emanuele Cencini, Alessandro Noto, Irene Dogliotti, Jacopo Olivieri, Marcello Riva, Isacco Ferrarini, Anna Maria Barbui, Sara Steffanoni, Dario Marino, Benedetta Puccini, Piero Maria Stefani, Rita Rizzi, Michele Merli, Angela Ferrari, Stefano Luminari, Carlo Visco, Livio Trentin, Andrea Visentin, Annarita Conconi, Simone Ferrero, Marzia Varettoni, Alessandra Tedeschi, Luca Laurenti, Francesco Piazza   +27 more
wiley   +1 more source

Efficacy and safety of telitacicept combined with immunosuppressive therapy for IgA nephropathy: a retrospective multicenter cohort study. [PDF]

Front Immunol
Zeng F, Yang Y, Tan F, Li Y, Ren D, Cai C, Wang J, Yan W, Xie X, Wang Y, Yi L, Xu S, Liu D, Xu G.   +13 more
europepmc   +1 more source

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, EarlyView.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source

Maternal and Neonatal Outcomes in Preeclampsia With and Without Proteinuria. [PDF]

Cureus
Saha C, Chadha S, Agrawal N, Kille HC, Mahajan P.   +4 more
europepmc   +1 more source

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva, Guido Junge, Kenneth Kulmatycki, Robert Schmouder, Anna Schubart, Marie‐Anne Valentin   +5 more
wiley   +1 more source

The Prognostic Significance of Proteinuria Severity in Pregnancy: A Retrospective Cohort Study of Maternal and Neonatal Outcomes. [PDF]

J Clin Med
Boza B, Ersan F, Alpay V, Erenel H.
europepmc   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source